EGFR and breast carcinoma: Breast cancer cells lacking ALIX, a protein involved both in EGFR spatial regulation [134,135] and in EV secretion [133], displayed an enhancement of EGFR activation, as well as an impairment in PD-L1+ EV release which conferred a more immunosuppressive phenotype to the tumour cells [157].